Office of Procurement, Acquisition and Logistics (OPAL)

Stipulated in Public Law 102-585, Section 603 all brand name drugs must be made available for purchase under the 65 I B Schedule program at a not to exceed price as a condition for receiving payment from certain entities.

All affected suppliers must submit a proposal for a VA Schedule contract. We developed the Interim Agreement (IA) process to bridge the gap while negotiating a VA Schedule contract. The IA gives both the FSS Service and the supplier the time needed to move through the new offer review process, negotiations, and award of a new contract while allowing the supplier to immediately meet the requirements of P. L. 102-585.

This year we streamlined our interim agreement process for new suppliers and/or suppliers of new brand name drugs. As part of this process, suppliers are required to provide our office with

• All relevant information regarding the affected drugs;
• Relevant information on the company adding the items;
• Contact information for the company adding the items; and
• Registration in the Government’s System Award Management (SAM) database

Upon receipt of this information we will provide your company with the relevant paperwork required to execute an interim agreement. Submit all interim agreement related inquires, comments, and documentation to interim_agree.ammhinfss@va.gov

In addition to meeting the requirements of the 65 I B Schedule program, manufacturers of covered drugs must enter in to a Master Agreement (MA) and a Pharmaceutical Pricing Agreement (PPA) with the VA.

• Master Agreement.The Master Agreement stipulates that covered drugs must be made available on the VA Schedules program and outlines the vendor’s responsibilities and obligations associated with the PL. Specifically, the MA instructs vendors to enter into a Pharmaceutical Pricing Agreement and requires them to submit non–FAMP data to the VA to establish federal ceiling prices (FCP). The terms and conditions of this agreement are non–negotiable and the same for all 65 I B contractors. This is an evergreen document and, as such, does not expire.
• Pharmaceutical Pricing Agreement.Through the Pharmaceutical Pricing Agreement, contractors agree that the annual FCP for each covered drug constitutes the maximum price that may be charged to the Government. Through Addendum A to the PPA, contractors provide a complete list of their available covered drugs. This list includes the product names, all applicable NDC numbers, and the current FCP for each drug. Contractors are required to update the PPA annually during the Public Law season.

Since implementation of P.L. 102-585, section 603, VA has issued numerous policy documents in the form of Dear Manufacturer Letters (DML). DMLs provide insight into VA’s current thoughts on issues and offer guidance and best practices with respect to the administration, promulgation, and compliance with the law. Download the archive (ZIP, 16.8 MB) all DML’s issued by VA since 1992. Please see our new 2025 Supplemental DML (10/01/2025) that provides new guidelines on New Package Size (NPS). This is a revision of previous guidance issued in the DML dated May 4, 2021.

Download the 2026 P.L. 102-585 Covered Drug Pricing Request for Modification. We will only process RFMs submitted using this year’s forms.

Send requests ammhin.pl102585@va.gov and cc your assigned contract specialist. To ensure receipt of your firm’s request for modification, the Subject Line must have the following identifying information: RFM-Contract Number-PL2026

Continue to send all non-Public Law modifications to the FSS Help Desk, fss.help@va.gov.

Modification requests submitted with missing or inaccurate information; or changes to the spreadsheet submitted after December 1, 2025 may have an adjusted effective date of January 15, 2026 or later. As a result, your firm may be subject to the penalties outlined in PL 102-585.

This is an abbreviated timeline. See the PBM and FSS Guidance for full instructions and due dates.

10/01 - FSS Instruction Letter Submitted to vendor by NAC.

10/17 - Receive Excel workbook with covered drug NDCs from PBM (if you have not received your workbook, please request from NonFamp@va.gov (Include FSS Contract Number in the subject line)

10/24 – PBM will begin calculating changes in the Non-FAMP pricing, additional discounts, and 2026 FCP. You will have three business dates to dispute or resubmit calculations to PBM, OGC, and OIG.

10/31 – Report modifications in the methodology used to calculate NFAMP to PBM, OGC, and OIG

10/31 – Report any disputes of the FSS pricing on 9/30/2025 or the old NFAMP entries.

11/15 – Submit annual NFAMP reports with FY2025, and calendar Q3 2025 calculation results to PBM.

12/1 – The authorized official who signed your firm’s PPA Addendum for 2026 FCPs (or an authorized successor) must prepare and sign a new PPA Addendum. Submit a properly prepared request for the modification package to incorporate updated pricing into your FSS contract. To ensure receipt of your firm’s request for modification, the Subject Line must have the following identifying information:

RFM-Contract Number-PL2026
Email your completed package to: ammhin.pl102585@va.gov and your assigned contract specialist.